Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk.

Wan-Chun Huang et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 4,600 people · 2021

Not counted

Reduced deaths

−35%−50% to −15%

Bigger than 8 in 10 for all-cause mortality

As reported

HR 0.65, 95% CI 0.50–0.85 · the paper's word: All-cause mortality

Not counted

Reduced deaths

−60%−72% to −41%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.40, 95% CI 0.28–0.59 · the paper's word: All-cause mortality

Not counted

Reduced deaths

−46%−66% to −13%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.54, 95% CI 0.34–0.87 · the paper's word: All-cause mortality

Three numbers in the abstract

the abstract, start to end

… composite CVD outcome (hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.50-0.85; p < 0.01), all-cause mortality (HR 0.40; 95% CI 0.28-0.59; p < 0.0001), and nonfatal stroke (HR 0.54; 95% CI 0.34-0.87; p = 0.01).

← favours treatmentfavours comparator →

could be chance

All-cause mortality

HR 0.650.50–0.85

All-cause mortality

HR 0.400.28–0.59

All-cause mortality

HR 0.540.34–0.87

GLP-1 receptor agonistsAll-cause mortality

1 / 3

7 papers cite it

2021

2022

2023

2024

2025

2026

this paperpooled itcites it

Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk.

What the trial testedas reported · 4,600 people · 2021

Reduced deaths

Reduced deaths

Reduced deaths

Three numbers in the abstract

Where each one falls

Where it lands on the map

7 papers cite it